bioAffinity Technologies, Inc. has released its financial results for the third quarter ended September 30, 2026, as detailed in a recent filing. This report is significant for the company as it provides insights into its operational performance and financial health during a critical period.
Based in San Antonio, Texas, bioAffinity Technologies operates within the Services-Commercial Physical & Biological Research sector, as denoted by its SIC code 8731. The company is publicly traded on the Nasdaq under the ticker symbols BIAF and BIAFW. It is classified as a non-accelerated filer and an emerging growth company.
The recent filing, dated November 6, 2026, indicates that the company issued a press release containing its financial information for the third quarter. The filing states, "On November 6, 2026, bioAffinity Technologies, Inc. issued a press release that included financial information for its third quarter ended September 30, 2026." This information is attached as Exhibit 99.1 to the filing.
The financial results reported could have implications for various stakeholders, including investors, analysts, and competitors in the commercial physical and biological research industry. Investors will likely scrutinize the results to gauge the company's growth trajectory and operational efficiency.
As for the next steps, the filing does not specify any forthcoming actions or events related to these results. Stakeholders will be keen to see how bioAffinity Technologies leverages this information in future strategies and communications.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










